BD55-1205 for COVID-19

 BD55-1205 has been reported as potentially beneficial for COVID-19 in the following studies.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed BD55-1205 in detail.
Gao et al., Dual frameworks for durable antibodies against SARS-CoV-2: Immune trajectories and viral fitness constraints, hLife, doi:10.1016/j.hlife.2025.10.002
Kuroda et al., Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silico, Human Vaccines & Immunotherapeutics, doi:10.1080/21645515.2025.2526873